Technological advances and the increasing availability of genomic data and computational systems have resulted in new methods to systematically identify both drug targets and pathways for detecting drugs with a secondary, often times seemingly unrelated, indication. The Roundtable on Translating Genomic-Based Research for Health hosted a workshop to assess the current landscape of drug repurposing activities in industry, academia, and government, examine enabling tools and technology, and evaluate the business models and economic incentives for drug repurposing programs.